SG11202003912RA - Single Domain Antibodies that Bind to CD137 - Google Patents

Single Domain Antibodies that Bind to CD137

Info

Publication number: SG11202003912RA
Authority: SG; Singapore
Prior art keywords: bind; single domain; domain antibodies; antibodies; domain
Prior art date: 2017-11-13

Application number

SG11202003912RA

Inventor

Verena Brucklacher-Waldert

Carolyn Edwards

James Legg

Jayesh Majithiya

Brian Mcguinness

Christine Rossant

Yumin Teng

Original Assignee

Crescendo Biologics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-11-13

Filing date

2018-11-13

Publication date

2020-05-28

2017-11-13 Priority claimed from GBGB1718735.2A external-priority patent/GB201718735D0/en

2017-11-13 Priority claimed from GBGB1718734.5A external-priority patent/GB201718734D0/en

2018-05-24 Priority claimed from GBGB1808589.4A external-priority patent/GB201808589D0/en

2018-11-13 Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd

2020-05-28 Publication of SG11202003912RA publication Critical patent/SG11202003912RA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

SG11202003912RA 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137 SG11202003912RA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB1718735.2A GB201718735D0 (en)	2017-11-13	2017-11-13	Bispecific molecules that bind to CD137 and PSMA
GBGB1718734.5A GB201718734D0 (en)	2017-11-13	2017-11-13	Single domain antibodies that bind to CD137
GBGB1808589.4A GB201808589D0 (en)	2018-05-24	2018-05-24	Single domain antibodies that bind CD137
PCT/GB2018/053279 WO2019092451A1 (en)	2017-11-13	2018-11-13	Single Domain Antibodies that Bind to CD137

Publications (1)

Publication Number	Publication Date
SG11202003912RA true SG11202003912RA (en)	2020-05-28

Family

ID=64457031

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11202003978UA SG11202003978UA (en)	2017-11-13	2018-11-13	Molecules that bind to cd137 and psma
SG11202003912RA SG11202003912RA (en)	2017-11-13	2018-11-13	Single Domain Antibodies that Bind to CD137

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11202003978UA SG11202003978UA (en)	2017-11-13	2018-11-13	Molecules that bind to cd137 and psma

Country Status (10)

Country	Link
US (2)	US20200362047A1 (en)
EP (2)	EP3710478A1 (en)
JP (3)	JP7312168B2 (en)
KR (2)	KR20200080304A (en)
CN (2)	CN111699197A (en)
AU (2)	AU2018363292A1 (en)
CA (2)	CA3082321A1 (en)
IL (2)	IL274370A (en)
SG (2)	SG11202003978UA (en)
WO (2)	WO2019092452A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3402825A1 (en)	2016-01-12	2018-11-21	Crescendo Biologics Limited	Molecules that bind prostate specific membrane antigen (psma)
GB201607968D0 (en)	2016-05-06	2016-06-22	Crescendo Biolog Ltd	Chimeric antigen receptor
EP3565840A1 (en)	2017-01-06	2019-11-13	Crescendo Biologics Limited	Single domain antibodies to programmed cell death (pd-1)
GB201711068D0 (en) *	2017-07-10	2017-08-23	Crescendo Biologics Ltd	Therapeutic molecules binding PSMA
WO2019092452A1 (en) *	2017-11-13	2019-05-16	Crescendo Biologics Limited	Molecules that bind to cd137 and psma
GB201802573D0 (en)	2018-02-16	2018-04-04	Crescendo Biologics Ltd	Therapeutic molecules that bind to LAG3
JP2020132572A (en) *	2019-02-20	2020-08-31	旭化成株式会社	Silanol composition, cured product, and production method
EP3969474A1 (en) *	2019-05-15	2022-03-23	Crescendo Biologics Limited	Binding molecules
CN113166265A (en) *	2019-08-12	2021-07-23	天境生物科技(上海)有限公司	Anti-claudin 18.2 and anti-4-1 BB bispecific antibodies and uses thereof
KR20220087479A (en) *	2019-11-13	2022-06-24	허페이 한커맵 바이오테크놀로지 컴퍼니 리미티드	Molecules capable of binding to human 4-1BB and applications thereof
MX2022005983A (en) *	2019-11-18	2022-09-07	Janssen Biotech Inc	Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof.
EP4155319A1 (en) *	2020-06-30	2023-03-29	Nona Biosciences (Suzhou) Co., Ltd.	4-1bb binding protein and application thereof
MX2023003041A (en)	2020-09-16	2023-05-09	Amgen Inc	Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer.
WO2022242682A1 (en) *	2021-05-21	2022-11-24	Beigene, Ltd.	Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
WO2022242679A1 (en) *	2021-05-21	2022-11-24	Beigene, Ltd.	Anti-cd137 antibodies and methods of use
CN113621065B (en) *	2021-08-30	2023-08-01	武汉海沙百得生物技术有限公司	Fully human antibody targeting 4-1BB, and preparation method and application thereof
KR20240049829A (en) *	2021-08-31	2024-04-17	라노바 메디신즈 리미티드 컴파니	Anti-4-1BB nanobody
WO2024040194A1 (en)	2022-08-17	2024-02-22	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
WO2024061364A1 (en) *	2022-09-22	2024-03-28	成都盛世君联生物技术有限公司	Anti-4-1bb nanobody, preparation therefor, and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0115256D0 (en)	2001-06-21	2001-08-15	Babraham Inst	Mouse light chain locus
GB2398784B (en)	2003-02-26	2005-07-27	Babraham Inst	Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
SG188175A1 (en) *	2004-06-03	2013-03-28	Novimmune Sa	Anti-cd3 antibodies and methods of use thereof
GB0521621D0 (en) *	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
WO2014141192A1 (en)	2013-03-15	2014-09-18	Erasmus University Medical Center	Generation of heavy chain-only antibodies
US11485790B2 (en) *	2014-04-07	2022-11-01	Chugai Seiyaku Kabushiki Kaisha	Immunoactivating antigen-binding molecule
US11547099B2 (en) *	2014-10-22	2023-01-10	Crescendo Biologies Limited	Transgenic mice
KR20170138574A (en)	2015-05-04	2017-12-15	피어이스 파마슈티컬즈 게엠베하	Anticancer fusion polypeptide
WO2016184882A1 (en) *	2015-05-18	2016-11-24	Pieris Pharmaceuticals Gmbh	Anti-cancer fusion polypeptide
WO2017060144A1 (en) *	2015-10-07	2017-04-13	F. Hoffmann-La Roche Ag	Bispecific antibodies with tetravalency for a costimulatory tnf receptor
CN108779176A (en) *	2016-01-11	2018-11-09	印希比股份有限公司	Multivalence and polyspecific 41BB combination fusion proteins
EP3402825A1 (en) *	2016-01-12	2018-11-21	Crescendo Biologics Limited	Molecules that bind prostate specific membrane antigen (psma)
CA3021618A1 (en)	2016-04-22	2017-10-26	Alligator Bioscience Ab	Novel bispecific polypeptides against cd137
EP3464367B1 (en) *	2016-05-27	2020-09-09	AbbVie Biotherapeutics Inc.	Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CA3075969A1 (en) *	2017-10-10	2019-04-18	Numab Therapeutics AG	Multispecific antibody
WO2019092452A1 (en)	2017-11-13	2019-05-16	Crescendo Biologics Limited	Molecules that bind to cd137 and psma

2018
- 2018-11-13 WO PCT/GB2018/053280 patent/WO2019092452A1/en active Application Filing
- 2018-11-13 JP JP2020526175A patent/JP7312168B2/en active Active
- 2018-11-13 SG SG11202003978UA patent/SG11202003978UA/en unknown
- 2018-11-13 KR KR1020207016093A patent/KR20200080304A/en not_active Application Discontinuation
- 2018-11-13 US US16/763,059 patent/US20200362047A1/en active Pending
- 2018-11-13 KR KR1020207016092A patent/KR20200083574A/en not_active Application Discontinuation
- 2018-11-13 EP EP18808058.4A patent/EP3710478A1/en active Pending
- 2018-11-13 CN CN201880085847.0A patent/CN111699197A/en active Pending
- 2018-11-13 SG SG11202003912RA patent/SG11202003912RA/en unknown
- 2018-11-13 EP EP18808057.6A patent/EP3710477A1/en active Pending
- 2018-11-13 JP JP2020526245A patent/JP2021502810A/en active Pending
- 2018-11-13 CA CA3082321A patent/CA3082321A1/en active Pending
- 2018-11-13 AU AU2018363292A patent/AU2018363292A1/en active Pending
- 2018-11-13 WO PCT/GB2018/053279 patent/WO2019092451A1/en active Application Filing
- 2018-11-13 AU AU2018363291A patent/AU2018363291A1/en active Pending
- 2018-11-13 CA CA3082297A patent/CA3082297A1/en active Pending
- 2018-11-13 US US16/763,063 patent/US20200362051A1/en active Pending
- 2018-11-13 CN CN201880086045.1A patent/CN111683968A/en active Pending
2020
- 2020-04-30 IL IL274370A patent/IL274370A/en unknown
- 2020-04-30 IL IL274371A patent/IL274371A/en unknown
2023
- 2023-07-06 JP JP2023111710A patent/JP2023126951A/en active Pending

Also Published As

Publication number	Publication date
WO2019092452A1 (en)	2019-05-16
IL274371A (en)	2020-06-30
JP7312168B2 (en)	2023-07-20
JP2021502810A (en)	2021-02-04
IL274370A (en)	2020-06-30
WO2019092451A1 (en)	2019-05-16
CA3082297A1 (en)	2019-05-16
US20200362047A1 (en)	2020-11-19
AU2018363291A1 (en)	2020-05-21
JP2021502104A (en)	2021-01-28
KR20200080304A (en)	2020-07-06
EP3710477A1 (en)	2020-09-23
KR20200083574A (en)	2020-07-08
JP2023126951A (en)	2023-09-12
CA3082321A1 (en)	2019-05-16
AU2018363292A1 (en)	2020-05-21
CN111699197A (en)	2020-09-22
EP3710478A1 (en)	2020-09-23
US20200362051A1 (en)	2020-11-19
SG11202003978UA (en)	2020-05-28
CN111683968A (en)	2020-09-18

Publication	Publication Date	Title
IL274370A (en)	2020-06-30	Single domain antibodies that bind to cd137
IL284336B (en)	2022-06-01	Antibody therapeutics that bind ctla4
IL276537A (en)	2020-09-30	Antibodies binding to gprc5d
IL254088A0 (en)	2017-10-31	Antibody therapeutics that bind cd137
IL261188A (en)	2018-10-31	Antibodies to tigit
HK1252863A1 (en)	2019-06-06	Antibody molecules which bind cd22
HK1252862A1 (en)	2019-06-06	Antibody molecules which bind cd45
IL254260A0 (en)	2017-10-31	Antibody therapeutics that bind tim3
IL275268A (en)	2020-07-30	Antibodies to lilrb2
EP3325009A4 (en)	2018-12-05	Antibody therapeutics that bind lag3
HK1256300A1 (en)	2019-09-20	Antibodies that specifically bind to tl1a
EP3247407A4 (en)	2018-08-22	Non-immunogenic single domain antibodies
ZA201907065B (en)	2020-09-30	Monoclonal antibody to pd-l1
EP3297662A4 (en)	2019-03-13	Antibodies that bind to axl proteins
IL269394A (en)	2019-11-28	Antibodies binding to steap-1
EP3131580A4 (en)	2017-11-08	Antibody therapeutics that bind cd147
IL273235A (en)	2020-04-30	Heavy chain antibodies binding to ectoenzymes
GB201609742D0 (en)	2016-07-20	Improvements relating to antibodies
EP3297663A4 (en)	2018-12-19	Antibodies that bind to axl proteins
ZA202002044B (en)	2022-08-31	Monoclonal antibody to il-5rα
SG10202010600SA (en)	2020-12-30	T cell receptor like antibodies that bind to p53-mhc class i complex
GB201718734D0 (en)	2017-12-27	Single domain antibodies that bind to CD137
GB201808589D0 (en)	2018-07-11	Single domain antibodies that bind CD137
IL272015A (en)	2020-02-27	Antibodies to MADCAM
GB201718735D0 (en)	2017-12-27	Bispecific molecules that bind to CD137 and PSMA